The Impact of COVID-19 is included in Tyrosine Kinase Inhibitor Market Report. Buy it today to get an advantage.
Request the impact of COVID-19 on your product or industry
Tyrosine Kinase Inhibitor Trends and Forecast
The future of the global tyrosine kinase inhibitor market looks promising with opportunities in the chronic myeloid leukemia, lung cancer, breast cancer, and renal cell cancer markets. The global tyrosine kinase inhibitor market is expected to reach an estimated $86.5 billion by 2030 with a CAGR of 8.0% from 2024 to 2030. The major drivers for this market are increasing prevalence of cancer and growing demand for targeted cancer therapies.
A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.
Tyrosine Kinase Inhibitor by Segment
The study includes a forecast for the global tyrosine kinase inhibitor by type, application, and region.
Tyrosine Kinase Inhibitor Market by Type [Shipment Analysis by Value from 2018 to 2030]:
• BCR-ABL Tyrosine Kinase Inhibitor
• Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
• Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors
• Others
Tyrosine Kinase Inhibitor Market by Application [Shipment Analysis by Value from 2018 to 2030]:
• Chronic Myeloid Leukemia
• Lung Cancer
• Breast Cancer
• Renal Cell Cancer
• Others
Tyrosine Kinase Inhibitor Market by Region [Shipment Analysis by Value from 2018 to 2030]:
• North America
• Europe
• Asia Pacific
• The Rest of the World
List of Tyrosine Kinase Inhibitor Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies tyrosine kinase inhibitor companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the tyrosine kinase inhibitor companies profiled in this report include-
• AstraZeneca
• Bayer
• Boehringer Ingelheim International
• Bristol-Myers Squibb
• Eisai
• F. Hoffmann-La Roche
• Johnson and Johnson
• Novartis
• Pfizer
• Eli Lilly
Tyrosine Kinase Inhibitor Market Insights
Lucintel forecasts that BCR-ABL is expected to witness highest growth over the forecast period.
Within this market, chronic myeloid leukemia is expected to witness highest growth over the forecast period.
North America will remain the largest region over the forecast period.
Features of the Global Tyrosine Kinase Inhibitor Market
Market Size Estimates: Tyrosine kinase inhibitor market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Tyrosine kinase inhibitor market size by type, application, and region in terms of value ($B).
Regional Analysis: Tyrosine kinase inhibitor market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the tyrosine kinase inhibitor market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the tyrosine kinase inhibitor market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the tyrosine kinase inhibitor market size?
Answer: The global tyrosine kinase inhibitor market is expected to reach an estimated $86.5 billion by 2030.
Q2. What is the growth forecast for tyrosine kinase inhibitor market?
Answer: The global tyrosine kinase inhibitor market is expected to grow with a CAGR of 8.0% from 2024 to 2030.
Q3. What are the major drivers influencing the growth of the tyrosine kinase inhibitor market?
Answer: The major drivers for this market are increasing prevalence of cancer and growing demand for targeted cancer therapies.
Q4. What are the major segments for tyrosine kinase inhibitor market?
Answer: The future of the tyrosine kinase inhibitor market looks promising with opportunities in the chronic myeloid leukemia, lung cancer, breast cancer, and renal cell cancer markets.
Q5. Who are the key tyrosine kinase inhibitor market companies?
Answer: Some of the key tyrosine kinase inhibitor companies are as follows:
• AstraZeneca
• Bayer
• Boehringer Ingelheim International
• Bristol-Myers Squibb
• Eisai
• F. Hoffmann-La Roche
• Johnson and Johnson
• Novartis
• Pfizer
• Eli Lilly
Q6. Which tyrosine kinase inhibitor market segment will be the largest in future?
Answer: Lucintel forecasts that BCR-ABL is expected to witness highest growth over the forecast period.
Q7. In tyrosine kinase inhibitor market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest region over the forecast period.
Q8. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the tyrosine kinase inhibitor market by type (BCR-ABL tyrosine kinase inhibitor, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors, BRAF kinase inhibitors, ROS1 inhibitors, and others), application (chronic myeloid leukemia, lung cancer, breast cancer, renal cell cancer, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Tyrosine Kinase Inhibitor Market, Tyrosine Kinase Inhibitor Market Size, Tyrosine Kinase Inhibitor Market Growth, Tyrosine Kinase Inhibitor Market Analysis, Tyrosine Kinase Inhibitor Market Report, Tyrosine Kinase Inhibitor Market Share, Tyrosine Kinase Inhibitor Market Trends, Tyrosine Kinase Inhibitor Market Forecast, Tyrosine Kinase Inhibitor Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.
Table of Contents
1. Executive Summary
2. Global Tyrosine Kinase Inhibitor Market : Market Dynamics
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. Market Trends and Forecast Analysis from 2018 to 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Tyrosine Kinase Inhibitor Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Tyrosine Kinase Inhibitor Market by Type
3.3.1: BCR-ABL Tyrosine Kinase Inhibitor
3.3.2: Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
3.3.3: Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors
3.3.4: Others
3.4: Global Tyrosine Kinase Inhibitor Market by Application
3.4.1: Chronic Myeloid Leukemia
3.4.2: Lung Cancer
3.4.3: Breast Cancer
3.4.4: Renal Cell Cancer
3.4.5: Others
4. Market Trends and Forecast Analysis by Region from 2018 to 2030
4.1: Global Tyrosine Kinase Inhibitor Market by Region
4.2: North American Tyrosine Kinase Inhibitor Market
4.2.2: North American Tyrosine Kinase Inhibitor Market by Application: Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer, and Others
4.3: European Tyrosine Kinase Inhibitor Market
4.3.1: European Tyrosine Kinase Inhibitor Market by Type: BCR-ABL Tyrosine Kinase Inhibitor, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors, and Others
4.3.2: European Tyrosine Kinase Inhibitor Market by Application: Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer, and Others
4.4: APAC Tyrosine Kinase Inhibitor Market
4.4.1: APAC Tyrosine Kinase Inhibitor Market by Type: BCR-ABL Tyrosine Kinase Inhibitor, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors, and Others
4.4.2: APAC Tyrosine Kinase Inhibitor Market by Application: Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer, and Others
4.5: ROW Tyrosine Kinase Inhibitor Market
4.5.1: ROW Tyrosine Kinase Inhibitor Market by Type: BCR-ABL Tyrosine Kinase Inhibitor, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors, and Others
4.5.2: ROW Tyrosine Kinase Inhibitor Market by Application: Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer, and Others
5. Competitor Analysis
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis
6. Growth Opportunities and Strategic Analysis
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global Tyrosine Kinase Inhibitor Market by Type
6.1.2: Growth Opportunities for the Global Tyrosine Kinase Inhibitor Market by Application
6.1.3: Growth Opportunities for the Global Tyrosine Kinase Inhibitor Market by Region
6.2: Emerging Trends in the Global Tyrosine Kinase Inhibitor Market
6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global Tyrosine Kinase Inhibitor Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Tyrosine Kinase Inhibitor Market
6.3.4: Certification and Licensing
7. Company Profiles of Leading Players
7.1: AstraZeneca
7.2: Bayer
7.3: Boehringer Ingelheim International
7.4: Bristol-Myers Squibb
7.5: Eisai
7.6: F. Hoffmann-La Roche
7.7: Johnson and Johnson
7.8: Novartis
7.9: Pfizer
7.10: Eli Lilly
.
Buy full report or by chapter as follows
Lucintel has been in the business of market research and management consulting since 2000 and has published over 1000 market intelligence reports in various markets / applications and served over 1,000 clients worldwide. This study is a culmination of four months of full-time effort performed by Lucintel's analyst team. The analysts used the following sources for the creation and completion of this valuable report:
In-depth interviews of the major players in this market
Detailed secondary research from competitors’ financial statements and published data
Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
A compilation of the experiences, judgments, and insights of Lucintel’s professionals, who have analyzed and tracked this market over the years.
Extensive research and interviews are conducted across the supply chain of this market to estimate market share, market size, trends, drivers, challenges, and forecasts. Below is a brief summary of the primary interviews that were conducted by job function for this report.
Thus, Lucintel compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. Lucintel then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process. The figure below is a graphical representation of Lucintel’s research process.
Please sign in below to get report brochure - Tyrosine Kinase Inhibitor Market Report.